RichardStanleyBedlackJr.MDPhD

Neurology • Durham, NC

Neuromuscular Medicine

Professor of Neurology, Duke University School of Medicine

Join to view full profile

Dr. Bedlack is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bedlack's full profile

Already have an account?

Office
501 Fulton Street
Box 111J
Durham, NC 27705
Phone+1 919-286-0411

Education & Training

Duke University HospitalResidency, Neurology, 1996 - 1999
Duke University HospitalInternship, Internal Medicine, 1995 - 1996
Uconn School Of MedicineClass of 1995

Certifications & Licensure

NC State Medical License 1995 - 2025
VA State Medical License 2000 - 2002
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Neuromuscular Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease Start of enrollment: 2006 May 01
Completed
Phase 2
A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients Start of enrollment: 2011 Sep 01
Completed
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis Start of enrollment: 2012 Jul 01
Completed
Not Applicable
Therapy in Amyotrophic Lateral Sclerosis (TAME) Start of enrollment: 2018 Nov 07
Completed
Phase 2
Clinical Trial of Ezogabine (Retigabine) in ALS Subjects Start of enrollment: 2015 Jun 01
Completed
Phase 2
ALS Reversals - Lunasin Regimen Start of enrollment: 2016 Apr 01
Completed
Phase 2
Study of ALS Reversals 2: Genetic Analyses Start of enrollment: 2018 Jun 22
Completed
A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS) Start of enrollment: 2018 Jun 21
Completed
Phase 1, Phase 2
Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2020 Aug 28
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

The Scientific and Therapeutic Rationale for Off-Label Treatments in Amyotrophic Lateral Sclerosis.
Richard Bedlack, Xiaoyan Li, Baggio Angelo Evangelista, Maria E Panzetta, Justin Kwan
Annals of Neurology. 2024-11-06
ALSUntangled #74: Withania Somnifera (Ashwagandha).
Sartaj Jhooty, Paul Barkhaus, Andrew Brown, Javier Mascias Cadavid, Gregory T Carter
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2024-11-01
ALSUntangled #76: Wahls protocol.
Xiaoyan Li, Paul Wicks, Andrew Brown, Akhil Shivaprasad, Maxwell Greene
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2024-10-09

Journal Articles

Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis
Brian J Wainger, Nicholas J Maragakis, Richard Bedlack, Namita A Goyal, Seward B Rutkove, Michael H Rivner, Stephen A Goutman, Shafeeq S Ladha, Elizabeth A Mauricio, R..., JAMA Neurology

Press Mentions

NIH to Fund Unproven ALS Drugs Under Patient-Backed LawOctober 1st, 2022
NIH to Fund Unproven ALS Drugs Under Patient-Backed LawOctober 1st, 2022
NIH to Fund Unproven ALS Drugs Under Patient-Backed LawOctober 1st, 2022
Join now to see all